Compare US Global Jets ETF (JETS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Recursion Pharmaceuticals Inc — how do they compare? US Global Jets ETF trades at $27.7 (market cap $878.48M), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.6× US Global Jets ETF's market cap, and US Global Jets ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JETS | RXRX | |
|---|---|---|
Market Cap | $878.48M | $2.31B |
Volume | 4,465,925 | 40,478,768 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $6.79 |
52-Week Low | $23.64 | $2.84 |
Typical Hold Time | 26 Days | 22 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Recent news highlights underperformance versus aerospace/defense ETFs, with competitors like ARKX and ITA showing stronger returns. Technical indicators show oversold conditions on short-term RSI but overall bearish momentum from moving averages.
The outlook remains challenged by fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term support at $27 could provide a technical floor, but sustained recovery requires easing of fuel cost pressures and improved airline earnings visibility. The ETF's concentration in pure airline operators increases sensitivity to industry-specific risks.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
